Table 1 Baseline characteristics of 5-ARI and non-5-ARI groups in the total cohort.
N (%) or Median (IQR) | Non-5-ARI group (N = 626) | 5-ARI group (N = 80) | P |
|---|---|---|---|
Age | 65.0 (58.0–71.0) | 69.0 (63.0–73.0) | <0.001 |
BMI | 24.5 (22.9–26.1) | 25.0 (22.6–26.5) | 0.664 |
Pre-biopsy PSA | 7.23 (4.91–11.05) | 5.56 (3.92–11.50) | 0.734 |
Pre-biopsy PSA (doubling) | 7.23 (4.91–11.05) | 11.12 (7.84–22.99) | 0.546 |
Prostate volume, total | 38.7 (28.5–51.1) | 41.0 (27.0–57.0) | 0.278 |
PSA density | 0.18 (0.12–0.31) | 0.13 (0.09–0.32) | 0.084 |
PI-RADSv2 category | 0.083 | ||
≤2 | 151 (24.2%) | 22 (27.5%) | |
3 | 216 (34.5%) | 30 (37.5%) | |
≥4 | 259 (41.4%) | 28 (35.1%) | |
Number of biopsy cores (Mean ± SD) | 14.2 ± 0.7 | 14.3 ± 0.8 | 0.492 |
Pathologic outcomes | |||
Total group | N = 626 | N = 80 | |
All cancer | 228 (36.4%) | 29 (36.3%) | 0.976 |
Clinically significant cancer* | 152 (24.3%) | 23 (28.8%) | 0.169 |
MRI-positive group** | N = 475 (75.9%) | N = 58 (72.5%) | 0.493 |
All cancer | 184 (38.7%) | 23 (39.7%) | 0.888 |
Clinically significant cancer* | 137 (28.8%) | 21 (36.2%) | 0.074 |
Duration of medication (years) | |||
Median (IQR) | — | 3.0 (2.0–5.0) | |
1–3, N (%) | — | 45 (56.3%) | |
≥3, N (%) | — | 35 (43.7%) | |
≥5, N (%) | — | 20 (25.0%) | |
